Formulations of 5-fluorocytosine and uses thereof
The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorouracil in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.
1. A method of treating a fungal infection or as part of a virotherapy with cytosine deaminase, comprising administering a gastro-retentive oral pharmaceutical composition 4 or less times per day for 7 days in a month, wherein the gastro-retentive oral pharmaceutical composition comprises a monolithic solid table form of 5-fluorocytosine (5-FC) comprising at least one hydrophilic matrix forming polymer of about 5 to 40 weight percent, hydroxymethyl cellulose (HPC) and microcrystalline cellulose (MCC) of about 5 to 30 weight percent, dicalcium phosphate of about 11 weight percent, magnesium stearate and opadry white and releases 5-FC into the upper gastrointestinal tract of a subject over a sustained period of time.
2. The method of claim 1 , wherein the weight ratio of 5-FC to the at least one hydrophilic polymer is about 5:1.
3. The method of claim 1 , wherein the weight ratio of the at least one hydrophilic polymer to HPC and MCC is about 1:2 to about 2:1.
4. The method of claim 1 , wherein the ratio of dicalcium phosphate to the at least one hydrophilic polymer is about 1:1.
5. The method of claim 2 , wherein the at least one hydrophilic matrix forming polymer is one or more of carbopol and/or kollidon.
6. The method of claim 3 , wherein the at least one hydrophilic matrix forming polymers make up about 8 weight percent to about 30 weight percent of the pharmaceutical composition.
7. The method of claim 1 , wherein 5-FC is present in the pharmaceutical composition at about 500 mg.
8. The method of claim 1 , wherein the pharmaceutical composition is administered at about 150 mg/kg/day for 7 days.
9. The method of claim 8 , wherein after 7 days of dosing of oral administration of the pharmaceutical composition to a fed subject at about 150 mg/Kg/day dosing schedule, the fed subject exhibits (i) a mean plasma concentration of 5-FC of between about 5 and 100 μg/ml.
10. The method of claim 1 , wherein following daily administration for 7 days or about 5 half-lives or more with 1-250 mg/Kg/day in divided doses to a fed human subject the mean serum concentration of 5-FC during a 24 hour period is about 1-200 μg/ml.
11. The method of claim 10 , wherein following daily administration for 7 days or about 5 half-lives or more with 1-250 mg/Kg/day in divided doses to a fed human subject the mean serum concentration of 5-FC during a 24 hour period is about 30-80 μg/ml.
12. The method of claim 1 , wherein the composition is administered 2-4 times per day.
13. The method of claim 1 , wherein the virotherapy with cytosine deaminase comprises an oncoretroviral vector having an internal ribosome entry site operably linked to a polynucleotide encoding a polypeptide having cytosine deaminase activity.